Patents Assigned to Aprogen, Inc.
-
Patent number: 11820831Abstract: Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.Type: GrantFiled: September 30, 2021Date of Patent: November 21, 2023Assignee: APROGEN INC.Inventors: Yoo Ri Moon, Sangsoon Yoon, Jeong Won Hong, Eun Jung Kim, Da Bin Choi
-
Patent number: 11542339Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.Type: GrantFiled: May 11, 2020Date of Patent: January 3, 2023Assignee: APROGEN INC.Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
-
Patent number: 10259860Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.Type: GrantFiled: October 31, 2007Date of Patent: April 16, 2019Assignee: APROGEN INC.Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh
-
Publication number: 20140073566Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: ApplicationFiled: March 20, 2013Publication date: March 13, 2014Applicant: Aprogen, Inc.Inventor: Aprogen, Inc.
-
Patent number: 8426570Abstract: The present invention relates to a recombinant expression vector for an animal cell containing a dihydrofolate reductase (DHFR) coding nucleotide sequence operatively linked to a DHFR promoter, to an animal cell line transformed by the vector, and to a method for preparing a target protein using the same. As compared with existing animal cell expression vectors, the vector of the present invention enables an effective screening of a cell line clone in which foreign genes are amplified together with DHFR genes even at a much lower methotrexate concentration. The present invention exhibits excellent effects in cell line preparation as high-productivity cell lines can be ensured in a short time through the use of a lower concentration of methotrexate in the process of protein production cell line establishment.Type: GrantFiled: July 7, 2009Date of Patent: April 23, 2013Assignee: Aprogen Inc.Inventors: Keun Soo Kim, Hye Kyung Ju, Choon Ju Jeon, Jae Seob Kim
-
Patent number: 8420353Abstract: A humanized antibody is produced by process comprising the steps of: (a) selecting a specificity determining residue (SDR) of the complementarity determining region (CDR) of murine monoclonal antibody heavy chain and light chain variable regions; and (b) grafting said SDR to at least one of the corresponding amino acid sequences in human antibody variable regions.Type: GrantFiled: March 22, 2003Date of Patent: April 16, 2013Assignee: Aprogen, Inc.Inventors: Hyo Jeong Hong, Cheol-Young Maeng, Gi-Hyeok Yang, Meong Hee Jang, Mee Sook Oh, Jin-Soo Song, Young Kug Jang
-
Patent number: 8414877Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: GrantFiled: May 17, 2012Date of Patent: April 9, 2013Assignee: Aprogen, Inc.Inventors: Gou Young Koh, Chung-Hyun Cho
-
Publication number: 20120251503Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: ApplicationFiled: May 17, 2012Publication date: October 4, 2012Applicant: Aprogen, Inc.Inventors: Gou Young KOH, Chung-Hyun Cho
-
Patent number: 8268316Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.Type: GrantFiled: March 10, 2006Date of Patent: September 18, 2012Assignee: Aprogen, IncInventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
-
Patent number: 8206698Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: GrantFiled: March 19, 2010Date of Patent: June 26, 2012Assignee: Aprogen, Inc.Inventors: Gou Young Koh, Chung-Hyun Cho
-
Publication number: 20110117643Abstract: The present invention relates to a recombinant expression vector for an animal cell containing a dihydrofolate reductase (DHFR) coding nucleotide sequence operatively linked to a DHFR promoter, to an animal cell line transformed by the vector, and to a method for preparing a target protein using the same. As compared with existing animal cell expression vectors, the vector of the present invention enables an effective screening of a cell line clone in which foreign genes are amplified together with DHFR genes even at a much lower methotrexate concentration. The present invention exhibits excellent effects in cell line preparation as high-productivity cell lines can be ensured in a short time through the use of a lower concentration of methotrexate in the process of protein production cell line establishment.Type: ApplicationFiled: July 7, 2009Publication date: May 19, 2011Applicant: Aprogen Inc.Inventors: Keun Soo Kim, Hye Kyung Ju, Choon Ju Jeon, Jae Seob Kim
-
Publication number: 20110117104Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.Type: ApplicationFiled: March 10, 2006Publication date: May 19, 2011Applicant: Aprogen Inc.Inventors: Hyo Jeong Hong, Kyung Soo Inn, Nam Kyu Lim, Jung Whan Kim, Keun Soo Kim, Sang Yoon Lee, Se Yeon Kim, Hyun Jung Kang, Mee Sook Oh
-
Patent number: 7691366Abstract: The present application describes a fusion molecule that includes coiled coil domain, which renders the molecule soluble and provides potent activity.Type: GrantFiled: December 13, 2007Date of Patent: April 6, 2010Assignee: Aprogen Inc.Inventor: Gou Young Koh
-
Patent number: 7691365Abstract: The present application discloses a method of treating a disease that is treatable by therapeutic angiogenesis comprising administering to a needy subject an effective amount of a chimeric coiled coil molecule comprising a coiled-coil domain linked to a receptor binding domain of a ligand.Type: GrantFiled: September 28, 2005Date of Patent: April 6, 2010Assignee: Aprogen, Inc.Inventors: Gou Young Koh, Chung-Hyun Cho